World Journal of Surgical Oncology (Sep 2023)

Meta analysis of the diagnostic value of circulating miRNA in benign and malignant pulmonary nodules

  • Ziqiang Hong,
  • Baiqiang Cui,
  • Xiangdou Bai,
  • Hongchao Li,
  • Tao Cheng,
  • Yannan Sheng,
  • Yingjie Lu,
  • Xusheng Wu,
  • Dacheng Jin,
  • Jing Zhao,
  • Yunjiu Gou

DOI
https://doi.org/10.1186/s12957-023-03133-3
Journal volume & issue
Vol. 21, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Objective A meta-analysis was conducted to assess the impact of miRNAs in circulation on diagnosing benign and malignant pulmonary nodules (BPNs and MPNs). Methods Electronic databases such as Embase, PubMed, Web of Science, and The Cochrane Library were utilized for diagnostic tests of circulating miRNAs to diagnose BPNs and MPNs from the library creation to February 2023. Meta-analysis of the included literature was performed using Stata 16, Meta-Disc 1.4, and Review Manager 5.4 software. This study determined the combined sensitivity, specificity, diagnostic ratio (DOR), positive/negative likelihood ratios (PLR/NLR), as well as value of area under the receiver operating characteristic (ROC) curve. Results This meta-analysis included 14 publications and 17 studies. According to our findings, the pooled sensitivity for miRNA in diagnosing benign and malignant pulmonary nodules was 0.82 [95% CI (0.74, 0.88)], specificity was 0.84 [95% CI (0.79, 0.88)], whereas the DOR was 22.69 [95% CI (13.87, 37.13)], PLR was 5.00 [95% CI (3.87, 6.46)], NLR was 0.22 [95% CI (0.15, 0.32)], and the area under the working characteristic curve (AUC) of the subject was 0.89 [95% CI (0.86, 0.91)]. Conclusion Circulating miRNAs could be used with sensitivity, specificity, DOR, PLR, NLR, and AUC as biomarkers to diagnose pulmonary nodules (PNs). However, more research is needed to determine the optimum miRNA combinations for diagnosing PNs due to the significant heterogeneity on previous studies.

Keywords